Endometrial cancer is the most common gynecological malignancy. The sialylation changes have been established as a potential tumor marker for patients with endometrial cancer. CD BioGlyco has the confidence to provide our clients with first-class sialic acid analysis services in endometrial cancer.
Endometrial cancer is a type of cancer that begins in the layer of cells and forms the lining (endometrium) of the uterus. The uterus is the hollow, pear-shaped pelvic organ where a fetus grows and develops when a woman is pregnant. Endometrial cancer is also called uterine cancer. Endometrial cancer is mostly diagnosed at an early stage and has better outcomes.
Glycans participate in many cancer-associated events, so aberrant glycosylation has been recognized to be one of the hallmarks of cancer. The changes in cancer-associated glycosylation often involve sialic acids which play important roles in cell-cell interaction, recognition, and immunological response. Aberrant sialylation in endometrial cancer is related to tumor invasion and metastasis. A significant increase in serum levels of sialic acid in endometrial cancer cells. Elevated levels of sialylation have been linked to tumor growth, poor differentiation, inhibition of apoptosis, and chemoresistance. As a result, monitoring serum/plasma factors such as overall sialic acid content, sialidase activity, and sialyltransferase expression, as well as sialylation changes on specific serum glycoproteins may have useful clinical applications for the detection, staging, and prognosis of endometrial cancer.
Serum/plasma sialylation changes have been established as a potential tumor marker for patients with endometrial cancer. A variety of methods for the detection and estimation of free sialic acids and sialic acids bound to glycoproteins or glycolipids have been performed. Different modifications of the colorimetric/spectrophotometric protocols as well as various Fluorescence Assays, enzymatic assays, and chromatographic methods for sialic acid content determination have been developed to pursue higher sensitivity or specificity, and easy and fast procedures. For example, total sialic acid in serum samples is determined by the standard Ehrlich's method, a colorimetric assay. According to this method, the supernatant of serum containing sialic acid chemically reacted with Ehrlich's reagent and produced a colorimetric reaction that is quantitatively measured using a spectrophotometer. In addition, changes in protein glycosylation and protein concentration are used to identify potential tumor biomarkers. We provide the analysis of individual sialylated glycoproteins.
Fig.1 Sialic acid analysis in gynecological cancers. (Berghuis, 2022)
In particular, chromatographic separation allows the successful separation of the sialic acids from interfering compounds. We have published different chromatographic approaches for the determination of sialic acid content including direct approaches such as anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD), liquid chromatography-mass spectrometry (LC-MS), thin-layer chromatography (TLC) and high-performance liquid chromatographic (HPLC).
Many tumor-associated antigens detectable by monoclonal antibodies are glycoconjugates on the cell surface. Among the common tumor-associated carbohydrate structures include Sialyl Lewis an Antigen, Sialyl Lewis x Antigen, and Sialyl Tn Antigen. It is reported that especially sialyl Lewis x containing triantennary N-glycans are increased in endometrial cancer patients. In summary, serum sialylation changes of glycan-antigens containing sialic acids are valuable as cancer biomarkers for improving the diagnosis of various cancers as well as prognosis and patient stratification. Serum sialylation changes of sialic acid-containing carbohydrate antigens are valuable as cancer biomarkers for improving the diagnosis as well as prognosis and patient stratification of various cancers.
CD BioGlyco employs various approaches to provide our clients with professional and rapid sialic acid analysis services in endometrial cancer. If you would like to know more information about the service, please feel free to contact us.
Reference:
